Khawaja Jahangir, MD
Hematology & Oncology · Las Vegas, NVNPI 1184806663
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,803 of the $50,490 with a category attached, or 63.0%. 38 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 57.1% of the total. Reporting peaked in 2019 at $43,778 and has fallen 98.8% since, to $547 in 2025.
Across 188 payments — averaging $268.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$29K
- AstraZeneca$8K
- Pfizer$6K
- Seagen Inc.$5K
- Boston Scientific$411
- Amgen$401
- plus $2K from 32 others
Across 347 payments — averaging $7086.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$848K
- Merck$588K
- Genentech, Inc.$223K
- AstraZeneca$191K
- Daiichi Sankyo Inc.$138K
- Sanofi US Services Inc.$130K
- plus $340K from 11 others
What the payments were for
- Consulting fees$6,76513%
- Speaking & faculty fees$31,80363%
- Travel & lodging$7,55015%
- Food & beverage$4,0838%
- Education$2891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $28,849 |
| AstraZeneca | 12 | $7,617 |
| Pfizer | 26 | $6,193 |
| Seagen Inc. | 9 | $4,702 |
| Boston Scientific | 3 | $411 |
| Amgen | 20 | $401 |
| Novartis | 26 | $313 |
| Gilead(2 entities) | 8 | $196 |
| Novocure Inc. | 2 | $192 |
| Incyte Corporation | 3 | $145 |
| E.r. Squibb & Sons, L.L.C. | 7 | $131 |
| Foundation Medicine, Inc. | 1 | $122 |
| Genentech, Inc. | 1 | $122 |
| Johnson & Johnson | 3 | $116 |
| Secura Bio, Inc. | 1 | $114 |
| Merck | 5 | $98 |
| Medtronic | 1 | $87 |
| Genentech USA, Inc. | 4 | $78 |
| Ipsen Biopharmaceuticals, Inc | 1 | $67 |
| Daiichi Sankyo Inc. | 4 | $66 |
| Astellas Pharma US Inc | 3 | $49 |
| Sobi, Inc | 1 | $43 |
| Myovant Sciences Inc. | 2 | $40 |
| Dendreon Pharmaceuticals LLC | 2 | $40 |
| EMD Serono, Inc. | 2 | $35 |
| Blueprint Medicines Corporation | 1 | $32 |
| Adaptive Biotechnologies Corporation | 2 | $29 |
| Coherus Oncology, Inc. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| ADC Therapeutics America, Inc. | 1 | $23 |
| Tempus AI, Inc | 1 | $22 |
| Intuitive Surgical | 1 | $19 |
| Global Blood Therapeutics, Inc. | 1 | $18 |
| Exelixis Inc. | 1 | $17 |
| Sanofi | 1 | $15 |
| Bayer | 1 | $14 |
| Array Biopharma Inc | 1 | $13 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALUNBRIG$19,934
- TALZENNA$5,977
- TAGRISSO$2,911
- IMFINZI$1,665
- FARYDAK$343
- GENERAL EMBOLICS$263
- TheraSphere Y90 Glass Microspheres 10 GBq$147
- FOUNDATIONONE$122
- FOUNDATIONONE HEME$122
- FOUNDATIONONE CDX$122
- FOUNDATIONFOCUS$122
- FOUNDATIONONE LIQUID$122
- TECENTRIQ$122
How this compares
$50,490 in reported general payments places this provider in the 80th percentile of 82 hematology & oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 52 | $1,242,326 |
| CabometyxCabozantinib S-Malate | 27 | $924,037 |
| LenvimaLenvatinib Mesylate | 18 | $748,540 |
| ImbruvicaIbrutinib | 29 | $528,299 |
| XtandiEnzalutamide | 33 | $483,108 |
| TasignaNilotinib Hcl | 14 | $323,779 |
| TagrissoOsimertinib Mesylate | 16 | $314,973 |
| PomalystPomalidomide | 11 | $287,639 |
| ZejulaNiraparib Tosylate | 13 | $276,510 |
| CalquenceAcalabrutinib Maleate | 15 | $232,777 |
| IbrancePalbociclib | 15 | $218,193 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $160,082 |
| Abiraterone Acetate | 151 | $116,160 |
| EliquisApixaban | 79 | $59,544 |
| Lupron DepotLeuprolide Acetate | 13 | $23,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $17 | $924,03727 claims |
| AstraZenecaTagrisso, Calquence | $7,617 | $547,75031 claims |
| NovartisTasigna, Mekinist | $313 | $483,86126 claims |
| Astellas Pharma US IncXtandi | $49 | $483,10833 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $131 | $287,63911 claims |
| PfizerIbrance, Eliquis | $6,193 | $277,73794 claims |
| Johnson & JohnsonXarelto | $116 | $19,46717 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $25 | $21320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Las Vegas
- Nicholas VogelzangLas Vegas$397K
- Wolfram SamlowskiLas Vegas$235K
- Oscar GoodmanLas Vegas$211K
- Aaron GoodmanLas Vegas$134K
- Anuradha ThummalaLas Vegas$128K
- Ann WiermanLas Vegas$81K
- Heather AllenLas Vegas$78K
- Holavanahalli Keshava-PrasadLas Vegas$67K
- Edgardo FaylonaLas Vegas$53K
- Clark JeanLas Vegas$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.